The global steroid-free nasal sprays market was expected to be worth US$ 8,141.9 million in 2022 and US$ 8,577.5 million in 2023. The demand for steroid-free nasal sprays has increased, and this is having an impact on the number of regulatory approvals received by the industry, which is driving the introduction of new products. To increase sales in the market, manufacturers are primarily concentrating on obtaining regulatory licences. The steroid-free nasal sprays market will grow at a CAGR of 6.4% between 2023 and 2033, reaching a value of roughly US$ 15,908.1 million by 2033, according to Future Market Insights’ projections.
As per Future Market Insights’ latest industry analysis, the global Steroid-Free Nasal Sprays Market was valued at over US$ 7.7 Billion in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period, pushing the market size to US$ 14.9 Billion by 2032.
Request a Sample copy of this Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-15127
Steroid-free nasal sprays are medications that are directly delivered to nasal cavities with the avoidance of first-pass metabolism and also provide better bioavailability. It includes nasal antihistamine sprays, nasal decongestant sprays, nasal anticholinergic sprays, and nasal cromolyn sodium sprays.
There is a subsequent rise in the prevalence of allergic rhinitis worldwide due to several risk factors including urbanization and environmental pollutants. According to a recent study conducted in 2022, allergic rhinitis affects about 25% to 40% of the population worldwide. It also states that approximately 80% of allergic rhinitis symptoms develop before the age of 20.
Recently, there has been an increasing emphasis on mental illnesses due to the significant rise in cases of major depressive disorders. Among these, depression is a common mental disorder. According to WHO, approximately 280 million people of all ages suffer from depression.
Due to rising adverse effects of depression, manufacturers in the steroid-free nasal sprays market are focusing on introducing products that can be used for the treatment of these disorders in the most effective manner.
Moreover, an increased number of regulatory approvals have been observed in the steroid-free nasal sprays market which is propelling the launch of innovative products. Therefore, manufacturers in the market are focusing on getting regulatory approvals to improve sales in the market.
“Rising availability of generic nasal sprays, along with increasing promotional activities by manufacturers at online channels will boost sales of steroid-free nasal sprays over the assessment period,” says an FMI analyst.
Key Takeaways:
- Based on product type, sales of nasal antihistamine sprays will increase at a 5.9% CAGR through 2032.
- The aqueous by formulation segment dominated the steroid-free nasal sprays market with around 55.4% share in 2021.
- In terms of distribution channels, demand in the institutional segment will grow at a 6% CAGR through 2032.
- North America accounted for the highest share of 35.6% of the global steroid-free nasal sprays market share in 2021.
Discover The Power Of Methodology-Driven Insights: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15127
Competition Landscape:
Some of the prominent players in the global market are-
- Janssen Pharmaceutical, Inc.
- Astra Zeneca Plc.
- Cipla Ltd.
- Glenmark Pharmaceuticals
- Glaxosmithkline Plc.
- Novartis International AG
- Procter & Gamble
- Sanofi S.A. (Sanofi-aventis LLC.)
- Boehringer Ingelheim GmbH
- AdvaCare Pharma
- Bayer AG (Bayer Consumer Health
- Covis Pharma S.a.r.l.
- Nipro Corporation (NIPRO JMI Pharma Ltd.)
- Viatris Inc. (Meda Pharmaceuticals Inc.)
- Perrigo Company plc
- AptarGroup, Inc.
- Berry Global, Inc.
- URSATEC GmbH
- Gerresheimer AG
- Avantor, VWR International, LLC
Prominent players operating in the global steroid-free nasal sprays market are focusing on the development, launch, and approval of innovative products to improve their product portfolios. For instance:
- In February 2022, Glenmark Pharmaceuticals Limited along with SaNOtize Research & Development Corp. announced the launch of FabiSpray, the nitric oxide nasal spray for the treatment of COVID-19 in India.
- In March 2021, Cipla Limited announced that it has received final approval from the FDA for its abbreviated new drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg which is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex nasal spray.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the steroid-free nasal sprays market in its latest study, presenting a historical demand assessment of 2017 to 2021 and projections for 2022 to 2032. The global steroid-free nasal sprays market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Seize this Opportunity for Detailed Market Intel: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/15127
Steroid-Free Nasal Sprays Market by Category:
By Product:
- Nasal Antihistamine Sprays
- Nasal Decongestant Sprays
- Nasal Anticholinergic Sprays
- Nasal Cromolyn Sodium Sprays
- Others
By Formulation:
- Aqueous
- Suspension
- Nonaqueous-Based Solution
- Hydroalcoholic
- Emulsions
- Dry Powder/Micro Particles
By Distribution Channel:
- Institutional Sales
- Hospitals
- Specialty Clinics
- Community Clinics
- Public Health Agencies
- Others
- Retail Sales
- Retail Pharmacy
- Drug Stores
- Mail Order Pharmacy
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube